KNC Laboratories Co.,Ltd. (JP:6568)

:6568

6568

KNC Laboratories Co.,Ltd.

RESEARCH TOOLSreports

Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥1,051.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥10.41B

Enterprise Value¥10.93B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)13.5

Beta0.56

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.98%

Share Statistics

EPS (TTM)85.36

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio3.29

Price to Book (P/B)0.67

Price to Sales (P/S)1.04

P/FCF Ratio-26.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

Balance-sheet StrengthSteady equity growth and historically low leverage provide durable financial flexibility. A well-capitalized balance sheet reduces refinancing and solvency risk in a capital‑intensive chemicals business, enabling continued investment, M&A optionality, and resilience through demand cycles.

Revenue ReboundAn 11.2% revenue recovery after 2025's decline signals renewed end-market demand or improved commercial execution. Sustained top-line growth restores scale benefits, supports capacity utilization, and is a prerequisite for restoring longer‑term profitability if cost structure normalizes.

Operating Cash Flow RecoveryMaterial improvement in operating cash flow indicates better cash conversion from core operations, easing near‑term liquidity pressure. If maintained, stronger OCF supports reinvestment, working capital funding, and reduces reliance on external financing despite recent FCF weakness.

Bears Say

Persistent Negative Free Cash FlowConsecutive years of negative free cash flow constrain the company's ability to self‑fund capex, pay down debt, or increase distributions. In a capital‑intensive chemicals sector, persistent FCF deficits raise structural funding risk and limit strategic optionality over the medium term.

Margin And Profitability ErosionDeclining gross profit amid rising revenue suggests adverse mix, pricing pressure, or rising input costs. Sustained margin compression weakens earnings power and return on invested capital, reducing buffer against cyclicality and limiting cash generation even if sales recover.

Rising Debt TrendAn uptick in debt after years of low leverage increases financial risk if margins and FCF remain under pressure. Higher indebtedness narrows capital allocation choices, raises refinancing exposure, and could force tradeoffs between growth investment and balance‑sheet repair.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥1051.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥10.41B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 44 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on May 14, 2026. The company reported ¥85.36 earnings per share for the quarter, beating the consensus estimate of N/A by ¥85.36.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥16 which represents an annual dividend yield of 2.98%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥85.36 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

Established in 1985 and headquartered in Kobe, Japan, KNC Laboratories Co., Ltd. focuses on the innovation, creation, and fabrication of organic chemical products. Their extensive range of offerings is utilized across various industries, including pharmaceuticals, electronic chemistry, agrochemicals, energy, and environmental management. Furthermore, the company provides critical support services for both medicinal compounds and advanced functional chemicals.